ROS production and mitochondrial dysfunction driven by PU.1-regulated NOX4-p22phox activation in Aβ-induced retinal

Junran Sun1,2,3, Jieqiong Chen1,2,3, Tong Li1,2,3

  • 1Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Theranostics
|October 14, 2020
PubMed

Insights

Amyloid β deposition in age-related macular degeneration causes retinal damage. This study identifies transcription factor PU.1 as a key regulator of oxidative stress, suggesting it as a potential therapeutic target for AMD.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Biochemistry

Background:

  • Amyloid β (Aβ) deposition is central to age-related macular degeneration (AMD) pathogenesis.
  • Oxidative stress driven by Aβ contributes to retinal pigment epithelium (RPE) degeneration.
  • The precise mechanisms of Aβ-mediated RPE damage via overoxidation remain unclear.

Purpose of the Study:

  • To elucidate the role of overoxidation in Aβ-mediated RPE damage.
  • To identify key molecular regulators of oxidative stress in an AMD model.
  • To explore PU.1 as a potential therapeutic target for AMD.

Main Methods:

  • Proteomic analysis using tandem mass-tagged (TMT) mass spectrometry (MS) in an Aβ₁-40 mouse model.
  • Bioinformatic analysis to identify enriched pathways and hub proteins.
  • Validation using reactive oxygen species (ROS) assays, mitochondrial function tests, gene silencing, and chromatin immunoprecipitation (ChIP).

Main Results:

  • Over 4000 proteins were identified, with 1069 significantly altered by Aβ₁-40, enriched in oxidation pathways.
  • NADPH oxidases were identified as key mediators of Aβ-induced oxidative stress and mitochondrial dysfunction.
  • The transcription factor PU.1 was identified as a master regulator of NADPH oxidase activation, particularly the NOX4-p22phox complex.

Conclusions:

  • PU.1 acts as a critical regulator in Aβ-driven oxidative stress and RPE injury.
  • Silencing PU.1 reduces oxidative stress, improves mitochondrial function, and rescues retinal structure and function.
  • PU.1 represents a novel therapeutic target for managing excessive oxidative stress in AMD.

Related Concept Videos